Amedisys Inc (AMED) Shares Up Despite Recent Market Volatility

The stock price of Amedisys Inc (NASDAQ: AMED) has jumped by 0.25 compared to previous close of 83.78. Despite this, the company has seen a fall of -1.97% in its stock price over the last five trading days. zacks.com reported 2024-11-13 that The DOJ suggests that UNH’s acquisitions reflect a strategy of buying competitors rather than competing directly, potentially giving it control over multiple markets.

Is It Worth Investing in Amedisys Inc (NASDAQ: AMED) Right Now?

Amedisys Inc (NASDAQ: AMED) has a price-to-earnings ratio that is above its average at 33.44x. The stock has a 36-month beta value of 0.74. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 8 as “hold,” and 1 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for AMED is 32.03M, and at present, short sellers hold a 8.08% of that float. On December 20, 2024, the average trading volume of AMED was 519.52K shares.

AMED’s Market Performance

AMED stock saw a decrease of -1.97% in the past week, with a monthly decline of -6.68% and a quarterly a decrease of -13.30%. The volatility ratio for the week is 0.99%, and the volatility levels for the last 30 days are 1.36% for Amedisys Inc (AMED). The simple moving average for the last 20 days is -3.48% for AMED’s stock, with a simple moving average of -10.79% for the last 200 days.

Analysts’ Opinion of AMED

Many brokerage firms have already submitted their reports for AMED stocks, with Deutsche Bank repeating the rating for AMED by listing it as a “Hold.” The predicted price for AMED in the upcoming period, according to Deutsche Bank is $101 based on the research report published on July 29, 2024 of the current year 2024.

Truist gave a rating of “Hold” to AMED, setting the target price at $97 in the report published on June 07th of the previous year.

AMED Trading at -8.31% from the 50-Day Moving Average

After a stumble in the market that brought AMED to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.12% of loss for the given period.

Volatility was left at 1.36%, however, over the last 30 days, the volatility rate increased by 0.99%, as shares sank -6.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.11% lower at present.

During the last 5 trading sessions, AMED fell by -2.06%, which changed the moving average for the period of 200-days by -9.87% in comparison to the 20-day moving average, which settled at $87.02. In addition, Amedisys Inc saw -11.65% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at AMED starting from North Michael Paul, who proposed sale 11,221 shares at the price of $96.80 back on Nov 07 ’24. After this action, North Michael Paul now owns shares of Amedisys Inc, valued at $1,086,220 using the latest closing price.

Stock Fundamentals for AMED

Current profitability levels for the company are sitting at:

  • 0.08 for the present operating margin
  • 0.4 for the gross margin

The net margin for Amedisys Inc stands at 0.05. The total capital return value is set at 0.11. Equity return is now at value 7.58, with 3.98 for asset returns.

Based on Amedisys Inc (AMED), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at 0.55. The debt to equity ratio resting at 0.33. The interest coverage ratio of the stock is 5.64.

Currently, EBITDA for the company is 216.91 million with net debt to EBITDA at 1.12. When we switch over and look at the enterprise to sales, we see a ratio of 1.28. The receivables turnover for the company is 7.71for trailing twelve months and the total asset turnover is 1.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.19.

Conclusion

To sum up, Amedisys Inc (AMED) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts